FY2028 EPS Estimates for Insulet Raised by Leerink Partnrs

Insulet Co. (NASDAQ:PODD - Free Report) - Investment analysts at Leerink Partnrs lifted their FY2028 earnings per share estimates for Insulet in a research note issued on Monday, November 25th. Leerink Partnrs analyst M. Kratky now expects that the medical instruments supplier will earn $7.80 per share for the year, up from their prior estimate of $7.75. The consensus estimate for Insulet's current full-year earnings is $3.22 per share.

PODD has been the topic of several other research reports. Morgan Stanley upped their target price on shares of Insulet from $234.00 to $317.00 and gave the stock an "overweight" rating in a research note on Monday, November 11th. Piper Sandler increased their target price on Insulet from $230.00 to $285.00 and gave the company an "overweight" rating in a research note on Tuesday, September 17th. Raymond James lifted their target price on Insulet from $213.00 to $260.00 and gave the stock an "outperform" rating in a report on Monday, October 14th. Citigroup upped their price target on Insulet from $250.00 to $275.00 and gave the company a "buy" rating in a report on Tuesday, October 1st. Finally, Canaccord Genuity Group lifted their price objective on Insulet from $236.00 to $269.00 and gave the stock a "buy" rating in a report on Wednesday, September 25th. Three equities research analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company's stock. According to MarketBeat, Insulet presently has a consensus rating of "Moderate Buy" and a consensus price target of $253.27.

Insulet Stock Up 0.2 %

Shares of Insulet stock traded up $0.50 during midday trading on Wednesday, hitting $266.92. The company had a trading volume of 414,400 shares, compared to its average volume of 772,315. Insulet has a 52-week low of $160.19 and a 52-week high of $279.40. The company has a debt-to-equity ratio of 1.21, a quick ratio of 2.80 and a current ratio of 3.68. The stock has a market capitalization of $18.72 billion, a P/E ratio of 45.70, a P/E/G ratio of 4.08 and a beta of 1.22. The company has a 50 day moving average of $242.59 and a 200 day moving average of $212.36.

Hedge Funds Weigh In On Insulet

Several hedge funds have recently modified their holdings of the stock. Baillie Gifford & Co. raised its stake in Insulet by 20.7% during the third quarter. Baillie Gifford & Co. now owns 2,275,701 shares of the medical instruments supplier's stock valued at $529,669,000 after purchasing an additional 389,639 shares in the last quarter. Geode Capital Management LLC lifted its position in Insulet by 1.3% in the third quarter. Geode Capital Management LLC now owns 1,738,601 shares of the medical instruments supplier's stock worth $403,339,000 after buying an additional 22,850 shares during the last quarter. Clearbridge Investments LLC boosted its stake in Insulet by 6.0% during the second quarter. Clearbridge Investments LLC now owns 1,339,763 shares of the medical instruments supplier's stock worth $270,364,000 after buying an additional 75,526 shares during the period. American Century Companies Inc. increased its position in Insulet by 18.7% during the second quarter. American Century Companies Inc. now owns 885,669 shares of the medical instruments supplier's stock valued at $178,728,000 after acquiring an additional 139,246 shares during the last quarter. Finally, Westfield Capital Management Co. LP raised its stake in shares of Insulet by 27.6% in the third quarter. Westfield Capital Management Co. LP now owns 754,872 shares of the medical instruments supplier's stock valued at $175,697,000 after acquiring an additional 163,388 shares during the period.

About Insulet

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.